TOPIGEN CEO to Present at Sachs Associates 5th Annual North American Forum

TOPIGEN Pharmaceuticals Inc., a biopharmaceutical company specializing in innovative respiratory therapeutics, today announced that Paul Wotton, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Sachs Associates 5th Annual North American Forum for Investing & Partnering in Biotech & Medtech on March 14, 2006 at 1:55 p.m.

Dr. Wotton’s presentation will be held at The Fairmont Copley Plaza Hotel in Boston, MA, and he will be available for one-on-one meetings throughout the conference. The presentation will be accessible live via webcast and for replay at http://www.investorcalendar.com/CEPage.asp?ID=102465.

About TOPIGEN

TOPIGEN is a privately-held biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN’s pipeline includes small molecule and RNA-based therapeutics. The Company’s Phase II products and research programs are uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This pioneering approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit www.topigen.com.

About Sachs Associates

Sachs Associates is a leading international forum for those interested in investing and partnering in the biotech and medtech industries. Going into its fifth year, the meeting attracts over 500 of the brightest players in the industry and provides prime executive-level networking and deal-making opportunities. The event features executive round-tables, presentations by mid-caps, small-caps, IPO prospects and venture-backed biotech and medtech companies.

For more information about Sachs Associates, please visit www.sachsforum.com

 Corporate Contact: G. John Mohr TOPIGEN Pharmaceuticals, Inc. (973) 809-5582 Contact via http://www.marketwire.com/mw/emailprcntct?id=5E0D32C6237ADA79  IR/PR Contact: Donna LaVoie LaVoie Group (781) 596-0200 X103 Contact via http://www.marketwire.com/mw/emailprcntct?id=32AEC0877526B3D1  

SOURCE: TOPIGEN Pharmaceuticals